New from PharmaTimes Media is the Medical & Scientific Excellence Awards.Highlighting this important area of work within the pharmaceutical industry, the awards are designed to recognise the outstanding achievements of medical and scientific professionals. More: Medical & Scientific Excellence Awards
read moreWhen Mylan said last month that it would consider a sale, analysts were skeptical the company could find an interested buyer. But one of them is changing their tune. More: Could troubled Mylan swing a sale to private equity buyer?
read moreAfter a long court fight, NHS England has prevailed in a fight with two drugmakers over the off-label use of Avastin to treat wet age-related macular degeneration. More: English court backs NHS in fight with Bayer, Novartis over off-label Avastin
read moreFDA inspectors last month spent two weeks inspecting the plant of Chinese API maker Zhejiang Huahai Pharmaceutical after learning its valsartan contained an impurity that is a suspected carcinogen. More: FDA berates Chinese drugmaker tied to global valsartan recall Source:
read moreThe EMA’s drug review panel is on fire this week. It recommended 13 medicines—including Eli Lilly’s CGRP player Emgality—for approval, nixed Sarepta’s controversial DMD therapy Exondys after re-examination and backed seven drugs’ indication expansion applications. More: Lilly’s CGRP Emgality and
read moreAcadia suffered from a safety controversy this year on its only marketed drug, Nuplazid, but the FDA again endorsed it after another review. More: FDA endorses Acadia's Nuplazid after review of deaths tied to drug Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals